seal

Amgen’s Trebananib Does Not Meet Overall Survival Endpoint in Phase Study of Ovarian Cancer Patients

Angiopoietin inhibitor, trebananib, did not extend overall survival (OS) in a Phase 3 study in ovarian cancer. In the TRINOVA-1 trial of 900 women with recurrent ovarian cancer following platinum-based chemotherapy, patients receiving trebananib plus paclitaxel had a 19.3 month overall survival versus 18.3 months OS for women receiving paclitaxel, alone.  The difference was not statistically significant. Continue reading

cancerBiology180x110

Reprogramming Lung Cancer to Self-Destruct Using TRAIL and CDK9 Inhibitor

CANCER RESEARCH UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells – paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool next week. This process is known as apoptosis. Continue reading

cancerBiology180x110

Super Enhancer Switches for Gene Regulation – Syros

Biotech company Syros Pharmaceuticals just raised $53.1 MM in a Series B financing after raising a $30 MM Series A financing in 2013. This is big money for a small company – and, the money comes from some very savvy biotech investment funds. Continue reading

cancerBiology180x110

Unum’s Antibody-Directed T Cells: Differentiated from CAR T-Cell and T Cell Receptor Reprogramming

Unum Therapeutics is a new immunotherapy biotechnology company in which Fidelity Biosciences, Atlas Ventures and Sanofi invested $12 MM in a Series A (first venture round) of investment. Continue reading

cancerBiology180x110

Lentiviral Vectors for Gene Transfection in CAR T-cell Therapy

Novartis entered into a $90 MM deal with Oxford Biomedica for use of its lentiviral vectors with its CAR (chimeric antigen receptor) modified T-cell product, CTL019, being developed with researchers at UPENN. Continue reading

seal

IND for Clinical Studies of dCellVax Breast Cancer Immune Therapy Filed – Intelligent and Rational Gene Silencing Approach for Cancer

Regen Biopharma recently filed an IND (Investigational New Drug Application) with the FDA to permit the initiation of Phase 1 clinical trials of its dCellVax treatment for advanced breast cancer. Continue reading

cancerBiology180x110

The Texas 2 Step Approach to Cancer Cyberwarfare via Exosomes

Multi-modality (surgery, chemo, radiation) therapy and combination chemotherapy (e.g, CHOP and ABVD) have long been the mainstays of treating cancer. So, we should not be surprised to read about the discovery made by scientists at Rice University and MD Anderson regarding a two-step approach involving radiation and immunotherapy. Continue reading

cancerBiology180x110

Chop Protein Suppresses the Immune Response in Cancer

The Chop protein, not to be confused with the CHOP chemotherapy regimen for lymphoma (Cyclophosphamide, Hydro doxorubicin – Adriamycin, Oncovin – vincristine, and Prednisone), is a multifunctional transcription factor. This 29 kda protein that is produced following unfolded protein stress in the endoplasmic reticulum, which then triggers apoptosis. Continue reading